Delnib 2% Cream for Chronic Hand Eczema (Delgocitinib) 10g
Pay in 3 Installments of
Rs.
958
JazzCash
easypaisa
NayaPay
Bank transfer
Cash on Delivery
Description
About Delnib 2% Cream
Delnib 2% Cream by Horizon Pharmaceuticals is a topical pan-JAK inhibitor containing Delgocitinib 2% (20 mg/g). By simultaneously inhibiting JAK1, JAK2, JAK3, and TYK2, it suppresses the key inflammatory cytokines — IL-4, IL-13, IL-17A, and IFN-γ — that drive the persistent itch, pain, and skin barrier damage characteristic of chronic hand eczema (CHE). Delivering active relief directly to affected skin, Delnib minimises systemic exposure compared to oral JAK inhibitors.
Key Benefits
- Pan-JAK Inhibition: Blocks all four JAK enzymes simultaneously, providing comprehensive suppression of the inflammatory cascade underlying chronic hand eczema.
- Clinically Proven: Phase III DELTA 1 & 2 trials demonstrated up to 37.7% treatment success versus vehicle after 16 weeks of twice-daily application.
- Relieves Itch & Pain: Significantly reduces Hand Eczema Symptom Diary (HESD) scores, including itch intensity and pain — two of the most debilitating symptoms of CHE.
- Topical & Targeted: Localised action on the hands with minimal systemic absorption, a safer profile than oral JAK inhibitors for hand-confined disease.
- Sustained Efficacy: Long-term safety and efficacy demonstrated for up to 52 weeks in the Phase III DELTA 3 open-label extension trial.
Indications
Delnib 2% Cream is indicated for moderate-to-severe chronic hand eczema in adults, particularly those with an inadequate response to, or intolerance of, topical corticosteroids. It forms part of the Eczema Care range at Derma.pk and sits alongside other medicated creams for targeted skin condition management. Use under the supervision of a qualified dermatologist.
Composition
Each gram contains Delgocitinib 20 mg (2%) in a cream base. Available in a 10 g tube. Browse the full Skin Care range at Derma.pk for more dermatologist-recommended products.
Precautions
For external use only. Avoid use on infected skin without appropriate antimicrobial cover. Not recommended during pregnancy or lactation without medical advice. Discontinue and consult your dermatologist if adverse reactions occur.
Usage & Benefits
- Pan-JAK Inhibition: Blocks JAK1, JAK2, JAK3, and TYK2 simultaneously, suppressing the full range of inflammatory cytokines that drive chronic hand eczema.
- Clinically Proven: Phase III DELTA 1 & 2 trials showed up to 37.7% treatment success after 16 weeks of twice-daily use versus vehicle control.
- Relieves Itch & Pain: Significantly reduces Hand Eczema Symptom Diary (HESD) scores, providing measurable relief from itch intensity and pain.
- Topical & Targeted: Localised cream delivery to the hands minimises systemic absorption compared to oral JAK inhibitors.
- Sustained Efficacy: Safety and effectiveness maintained for up to 52 weeks in the Phase III DELTA 3 open-label extension study.
How To Use
1. Cleanse and gently dry the affected area on the hands before each application.
2. Apply a thin layer of Delnib 2% Cream to the affected skin on the hands twice daily — once in the morning and once in the evening.
3. Wash your hands after applying unless the hands are the area being treated.
4. Avoid contact with eyes, mouth, and open wounds.
5. Use consistently as directed by your dermatologist. Do not exceed the prescribed treatment duration.
FAQs
What is Delnib 2% Cream used for?
Delnib 2% Cream is indicated for moderate-to-severe chronic hand eczema (CHE) in adults, especially those who have not responded adequately to topical corticosteroids or for whom corticosteroids are not suitable.
What is the active ingredient in Delnib 2% Cream?
The active ingredient is Delgocitinib 2% (20 mg/g), a topical pan-JAK inhibitor that blocks JAK1, JAK2, JAK3, and TYK2 enzymes to reduce the inflammatory pathways driving hand eczema.
How often should Delnib 2% Cream be applied?
Apply a thin layer twice daily — once in the morning and once in the evening — to clean, dry, affected skin on the hands, as directed by your dermatologist.
Is Delnib 2% Cream safe for long-term use?
Clinical trials (Phase III DELTA 3) have demonstrated the safety and efficacy of Delgocitinib cream for up to 52 weeks. Always use under the guidance of a dermatologist for extended or ongoing treatment.
Can Delnib 2% Cream be used during pregnancy or breastfeeding?
Use during pregnancy or lactation is not recommended without explicit medical advice. Consult your dermatologist before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
